Peter Fibiger Bang

Safety and immunogenicity of the chlamydia vaccine candidate CTH522 adjuvanted with CAF01 liposomes or aluminium hydroxide: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial

Sonya Abraham, Helene Bæk Juel, Peter Fibiger Bang et al. · The Lancet Infectious Diseases · 2019 · 205 citations

Veterinary Medicine, Immunology, Infectious Diseases +16

Ag85B–ESAT-6 adjuvanted with IC31® promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naïve human volunteers

Jaap T. van Dissel, Sandra M. Arend, Corine Prins et al. · Vaccine · 2010 · 202 citations

Life Sciences, Immunology, Microbiology +13

First-in-human trial of the post-exposure tuberculosis vaccine H56:IC31 in Mycobacterium tuberculosis infected and non-infected healthy adults

Angelique Kany Kany Luabeya, Benjamin M. Kagina, Michèle Tameris et al. · Vaccine · 2015 · 194 citations

Veterinary Medicine, Immunology, Infectious Diseases +15

Antigen Availability Shapes T Cell Differentiation and Function during Tuberculosis

Albanus O. Moguche, Munyaradzi Musvosvi, Adam Penn‐Nicholson et al. · Cell Host & Microbe · 2017 · 188 citations · Full text

Life Sciences, Immunology, Infectious Diseases +10

A double-blind, randomized trial of IV immunoglobulin treatment in acute optic neuritis

Hanne Roed, Annika Reynberg Langkilde, Finn Sellebjerg et al. · Neurology · 2005 · 142 citations

Medicine, Neurology, Ophthalmology +15